High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Slides:

Advertisements

Similar presentations

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Advertisements

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Su K. Metcalfe, MD, MPH, Michael T

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer? Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer Jeong-Ok Lee, MD, Tae Min.

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin Park, MD, Sook-Whan Sung, MD, PhD, Jeong-Wook Seo, MD, PhD, Doo Hyun Chung, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 3, Pages 305-313 (March 2010) DOI: 10.1097/JTO.0b013e3181ce3d1d Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 FISH images from MET FISH+ NSCLCs. A, A case with MET high polysomy showed more than 4 copies of the MET gene (orange signal) in more than 40% of tumor cells. B, An example of MET amplification revealed small (4–10 copies) or innumerable tight MET gene clusters or more than 15 copies of the MET gene in more than 10% of tumor cells. The MET to CEP7 (green signal) ratio exceeded 2. NSCLC, nonsmall cell lung cancer; FISH, fluorescence in situ hybridization. Journal of Thoracic Oncology 2010 5, 305-313DOI: (10.1097/JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier curves using the log-rank test showing the overall survival of all NSCLC patients (A, B), NSCLC patients with MET FISH+ (C), NSCLC patients with stage III–IV (D), and SCC patients (E, F) according to the MET FISH+ and FISH−, or MET gene amplification status based on the UCCC criteria. NSCLC, nonsmall cell lung cancer; FISH, fluorescence in situ hybridization; SCC, squamous cell carcinoma; UCCC, the University of Colorado Cancer Center. Journal of Thoracic Oncology 2010 5, 305-313DOI: (10.1097/JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier curves using the log-rank test showing the overall survival of MET FISH+ and FISH−, or gene copy number status according to EGFR FISH− NSCLCs, (A, B) and EGFR FISH+ NSCLCs (C, D). FISH, fluorescence in situ hybridization; NSCLC, nonsmall cell lung cancer; EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2010 5, 305-313DOI: (10.1097/JTO.0b013e3181ce3d1d) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions